8-K: Myriad Genetics Q4 2025: Growth in Key Tests, New Launches

Myriad Genetics reported Q4 2025 financial results, showing revenue consistent with the prior year and growth in key test volumes, while reiterating 2026 financial guidance.

Summary

• Q4 2025 revenue was $209.8 million, consistent with Q4 2024, but grew 4% year-over-year when excluding an $8.1 million headwind from UnitedHealthcare's GeneSight coverage discontinuation.
• Full-year 2025 revenue was $824.5 million, a 2% decrease year-over-year, but a 2% increase excluding headwinds from UNH GeneSight discontinuation and the EndoPredict business divestiture.
• Key test volume growth in Q4 2025 year-over-year included Prolaris prostate cancer test at 12%, Hereditary cancer testing at 9%, and GeneSight mental health test at 9%.
• GAAP net loss for Q4 2025 was $7.9 million, or $0.08 per share, while adjusted EPS was $0.04 per share and adjusted EBITDA was $14.3 million.
• The company reiterated its full-year 2026 revenue guidance of $860 million to $880 million, with Q1 2026 revenue expected between $200 million and $203 million.
• Three significant new test launches are planned for 2026: Precise MRD (alpha launch March 2026), AI-enabled Prolaris (commercial launch Q2 2026), and FirstGene (commercial launch H2 2026).
• Full-year 2025 GAAP net loss significantly widened to $365.9 million from $127.3 million in FY 2024, primarily due to $319.4 million in goodwill and long-lived asset impairment charges.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, reflecting operational improvements and strategic advancements in new product development, despite ongoing revenue headwinds and significant prior-year impairment charges. The reiterated 2026 guidance and positive Q4 adjusted metrics suggest a stable outlook, but the substantial full-year GAAP loss and increased debt warrant caution.

Positives

• Q4 2025 revenue grew 4% year-over-year when excluding the $8.1 million headwind from UnitedHealthcare's GeneSight coverage discontinuation.
• Strong year-over-year test volume growth in Q4 2025 for Prolaris (+12%), Hereditary cancer testing (+9%), and GeneSight (+9%).
• Q4 2025 GAAP net loss significantly improved to $7.9 million from $42.5 million in Q4 2024.
• Adjusted EPS for Q4 2025 increased to $0.04 per share from $0.03 per share in Q4 2024.
• Adjusted EBITDA for Q4 2025 increased to $14.3 million from $10.6 million in Q4 2024.
• Cash and cash equivalents increased to $149.6 million as of December 31, 2025, from $102.4 million at December 31, 2024.
• Net cash provided by operating activities for FY 2025 improved to $1.8 million from a use of $8.7 million in FY 2024.
• The company plans three significant new test launches in 2026: Precise MRD, AI-enabled Prolaris, and FirstGene.
• Positive interim outcomes reported for Precise MRD in a colorectal cancer study, showing 100% baseline sensitivity and highly sensitive detection of residual disease post-surgery.

Negatives

• Q4 2025 total revenue of $209.8 million was consistent with Q4 2024, showing no nominal growth.
• Full-year 2025 revenue decreased 2% year-over-year to $824.5 million.
• Q4 2025 Prenatal testing volume decreased 6% year-over-year, and revenue was stable year-over-year.
• Q4 2025 Mental Health (GeneSight) revenue decreased 10% year-over-year to $36.6 million, reflecting the impact of UnitedHealthcare's discontinuation of coverage.
• Full-year 2025 GAAP net loss significantly worsened to $365.9 million from $127.3 million in FY 2024, primarily due to $319.4 million in goodwill and long-lived asset impairment charges.
• Total assets decreased by $321 million from $1,027.6 million at December 31, 2024, to $706.6 million at December 31, 2025, largely due to impairment charges.
• Long-term debt increased significantly to $119.9 million at December 31, 2025, from $39.6 million at December 31, 2024.
• Total stockholders' equity decreased by $333.1 million from $701.1 million at December 31, 2024, to $368.0 million at December 31, 2025.

Risks

• Sales and profit margins of existing tests may decline.
• The company may not be able to operate its business on a profitable basis.
• Risks related to the company's ability to achieve certain revenue growth targets and generate sufficient revenue from its existing product portfolio or in launching and commercializing new tests to be profitable.
• Risks related to recent changes in the company's senior management team and the successful implementation of the company's strategic plan.
• Risks related to changes in governmental or private insurers' coverage and reimbursement levels for the company's tests or the company's ability to obtain reimbursement for its new tests at comparable levels to its existing tests.
• Risks related to increased competition and the development of new competing tests.
• The risk that the company may be unable to develop or achieve commercial success for additional tests in a timely manner, or at all.
• The risk that the company is not able to secure additional financing to fund its business, if needed, in a timely manner or on favorable terms, if at all.
• The risk that the company may not successfully develop new markets or channels for its tests.
• The risk that licenses to the technology underlying the company's tests and any future tests are terminated or cannot be maintained on satisfactory terms.
• Risks related to delays or other problems with operating the company's laboratory testing facilities.
• Risks related to public concern over genetic testing in general or the company's tests in particular.
• Risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems.
• Risks related to the company's ability to obtain new corporate collaborations or licenses and acquire or develop new technologies or businesses on satisfactory terms, if at all.
• Risks related to the company's ability to successfully integrate and derive benefits from any technologies or businesses that it licenses, acquires or develops.
• Risks related to the company's projections or estimates about the potential market opportunity for the company's current and future products.
• The risk that the company or its licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying the company's tests.
• The risk of patent-infringement claims or challenges to the validity of the company's patents.
• Risks related to changes in intellectual property laws covering the company's tests, or patents or enforcement, in the United States and foreign countries.
• Risks related to security breaches, loss of data and other disruptions, including from cyberattacks and other cybersecurity incidents.
• Risks of new, changing and competitive technologies in the United States and internationally and that the company may not be able to keep pace with the rapid technology changes in its industry, or properly leverage new technologies to achieve or sustain competitive advantages in its products.
• The risk that the company may be unable to comply with financial or operating covenants under the company's credit or lending agreements.
• The risk that the company may not be able to maintain effective disclosure controls and procedures and internal control over financial reporting.
• Risks related to current and future investigations, claims or lawsuits, including derivative claims, product or professional liability claims, and risks related to the amount of the company's insurance coverage limits and scope of insurance coverage with respect thereto.

Future Outlook

Myriad Genetics reiterated its full-year 2026 financial guidance, projecting revenue between $860 million and $880 million, adjusted gross margin of 68%-69%, and adjusted EBITDA of $37 million to $49 million. The company anticipates a milestone year with three significant new test launches: Precise MRD (alpha launch March 2026), AI-enabled Prolaris (commercial launch Q2 2026), and FirstGene (commercial launch H2 2026), which are expected to drive growth in 2027 and beyond. Q1 2026 revenue is projected at $200 million to $203 million, with adjusted EBITDA near breakeven.

Management Comments

• "We ended 2025 with positive momentum in a number of key areas, including within the Cancer Care Continuum where we drove another quarter of high single-digit volume growth in Hereditary cancer testing year-over-year and recognized improving volume growth for our Prolaris prostate cancer test."
• "I'm also pleased to report improving volume growth in our GeneSight mental health test. We attribute this momentum to strengthened execution across the commercial team and the enterprise overall."
• "Prenatal testing has been uneven through 2025 but we continue to make progress and expect growth to reaccelerate in the coming quarters."
• "2026 is a milestone year for Myriad Genetics, with three significant new test launches... We are looking forward to these tests supporting clinical decisions starting in 2026 and being important components of our growth in 2027 and beyond."

Industry Context

StockSavvy.ai notes that Myriad Genetics' focus on new test launches, particularly in AI-enabled diagnostics and molecular residual disease, aligns with broader industry trends towards precision medicine and advanced genomic testing. The challenges in prenatal testing and the impact of insurer coverage changes (like UnitedHealthcare's GeneSight discontinuation) highlight the volatile reimbursement landscape and competitive pressures in the diagnostics sector. The company's efforts to drive volume growth in key areas like hereditary cancer and Prolaris, despite overall revenue declines, suggest a strategic pivot towards higher-growth, higher-margin segments within a competitive market.

Comparison to Industry Standards

• The positive interim outcomes for Precise MRD in the MONSTAR-SCREEN-3 study, reporting 100% baseline sensitivity and highly sensitive detection of residual disease post-surgery in colorectal cancer patients, are strong indicators for a molecular residual disease test. This level of sensitivity is critical for early detection and monitoring in oncology, potentially positioning Precise MRD favorably against emerging competitors in the MRD space, such as Natera's Signatera or Guardant Health's Reveal, though direct comparative data is not provided in this filing.
• The launch of an integrated AI and genetic risk platform for breast cancer risk assessment, developed with Clairity and MagView, demonstrates an effort to leverage artificial intelligence in precision health, a growing trend seen across the diagnostic industry to enhance predictive capabilities and personalize patient care.

Legal Proceedings

• The reconciliation of non-GAAP financial measures for Q4 and FY 2024 includes a "reversal of $21.3 million related to the contingent settlement for the Ravgen litigation that is no longer considered probable." This indicates a past legal matter that has been resolved or whose probability of payment has changed.

Stakeholder Impact

• Shareholders: Mixed impact. Improved Q4 adjusted results and positive outlook for new products could be favorable, but the significant full-year GAAP net loss due to impairment and increased long-term debt are concerns. The reiterated 2026 guidance provides some stability.
• Customers (Patients/Providers): Positive impact from new test launches (Precise MRD, AI-enabled Prolaris, FirstGene) offering advanced diagnostic and precision medicine solutions. Continued volume growth in key tests like hereditary cancer and Prolaris indicates ongoing utility and demand.
• Employees: The mention of "strategic realignment" costs including severance in non-GAAP adjustments for FY 2025 suggests some workforce adjustments have occurred or are ongoing.
• Insurers: UnitedHealthcare's discontinuation of GeneSight coverage highlights ongoing challenges in reimbursement and coverage decisions, which can impact revenue.

Next Steps

• Targeted alpha launch of Precise MRD for breast cancer in March 2026.
• Full commercial launch of AI-enabled Prolaris prostate cancer test in partnership with PATHOMIQ in Q2 2026.
• Full commercial launch of the multiple prenatal screen test, FirstGene, in H2 2026.
• Continued progress and reacceleration of growth in prenatal testing in coming quarters.
• CONNECTOR study for FirstGene Multiple Prenatal Screen to support future commercial launch activities.
• Conference call on February 23, 2026, to discuss financial results and business developments.

Key Dates

Recommendation

The company demonstrates positive operational momentum in key test volumes and has a strong pipeline of new product launches for 2026, which could drive future growth. Q4 2025 adjusted financial metrics showed improvement, and 2026 guidance was reiterated, suggesting stability. However, the substantial full-year 2025 GAAP net loss, primarily due to significant impairment charges, and the increase in long-term debt present considerable financial headwinds. The mixed performance, with some segments facing revenue declines due to coverage issues and transition dynamics, suggests a 'hold' recommendation. Investors should monitor the successful commercialization of new tests and the company's ability to return to sustained GAAP profitability.

Keywords

Myriad Genetics, MYGN, Financial Results, Q4 2025, Full Year 2025, 2026 Guidance, Molecular Diagnostics, Precision Medicine, Genetic Testing, Hereditary Cancer, Prolaris, GeneSight, Precise MRD, FirstGene, Oncology, Women's Health, Mental Health, Earnings, Revenue, EBITDA, Net Loss, Test Volume